Gyre Therapeutics Q1 2024 revenue $27.2M, net income $9.9M; F351 Phase3 data due early 2025

GYRE THERAPEUTICS, INC.

2024-Q1 EPS reported $0.03 revenue$27,172,000

Revenue $27.2M (+9% YoY); net income $9.9M vs $4.2M; ETUARY sales $26.9M (+10% YoY).
Cash $29.8M as of March 31, 2024 (from $33.5M at Dec 2023); expects >12 months runway.
Phase 3 F351 for CHB liver fibrosis on track; topline data expected by early 2025.
U.S. IND for F351 in NASH fibrosis expected late 2024; Phase 2a trial planned in 2025.
Acquired nintedanib rights from Jiangsu Wangao to strengthen PRC pulmonary fibrosis franchise.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GYRE THERAPEUTICS, INC. reported the three months ended March 31, 2024 results: revenue $27.2 million.

Period: the three months ended March 31, 2024
Revenue: $27.2 million
Result: reported results

Exact text from the filing

of the condensed consolidated financial statements. Financial Results for the Quarter Ended March 31, 2024 • Revenues: For the three months ended March 31, 2024, revenues were $27.2 million as a result of Gyre’s indirect controlling interest in Gyre Pharmaceuticals. For the three months ended March 31, 2023, revenues were $24.9 million. The increase was driven by a

View on SEC.gov

1053 earnings releases filed in the last 30 days. Browse all earnings releases →

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-056893

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.